Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events
This article was originally published in The Pink Sheet Daily
Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.
You may also be interested in...
Goal is a 70/30 split of ROW and Japanese revenues, firm says.
Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)
FDA extends user fee date for the novel anti-platelet drug to Sept. 26.